Coronavirus Update: Gilead Says 'Inappropriate Characterizations' In Remdesivir Trial Flop Leak

Plus: J&J Finds Manufacturing Partner, AZ To Investigate Heart Complications

 
• By Scrip Team

The leaked abstract suggests remdesivir provides no benefits for patients - but analysts say conclusions are hard to draw from underpowered trial.

Vials_Remdesivir
Three Phase III readouts are expected in the next few weeks, which should provide a clearer picture on remdesivir

Data from a trial in China of Gilead Sciences Inc.’s antiviral treatment remdesivir have been posted by accident online by the World Health Organization, showing that the treatment did not improve the condition of patients with severe COVID-19 or reduce the presence of the virus in the bloodstream.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from COVID-19

More from Scrip